Xijing hospital
Xi'an, Shaanxi, 710032, China
Location status: Recruiting
NCT Number: NCT07071402
The aim of this clinical trial is to assess the feasibility and safety of ultrasound-guided vacuum-assisted excision (VAE) in the treatment of early breast cancer with Tis (carcinoma in situ) or T1 (maximum tumor diameter ≤2cm) and negative axillary lymph nodes on imaging. The main question it aims to answer is:
* After VAE, when undergoing routine breast cancer surgery again, what is the complete resection rate of the lesion in the surgically removed tissue (pathologically confirmed), that is, the false negative rate of VAE? * Which type of breast cancer lesion has the highest complete resection rate? * Is it clear whether VAE can be applied in the treatment of early breast cancer with Tis or T1 and negative axillary lymph nodes on imaging? * Do patients with benign breast nodules who undergo VAE or are recommended for Vacuum-assisted breast biopsy (VABB) due to limited puncture and are diagnosed with breast cancer need to undergo surgery again? * The incidence of complications of VAE.
Participants will:
* Single early breast cancer subjects with Tis or T1 and negative axillary lymph nodes on imaging, after being fully informed and signing the informed consent form, enter the trial period after screening and being qualified. * After the subjects are confirmed to be enrolled, VAE biopsy resection is performed first. * Patients clearly diagnosed with breast cancer receive traditional radical mastectomy for breast cancer: Breast-conserving surgery or total mastectomy, sentinel lymph node biopsy or dissection in the axilla, assessment of whether the lesion has been completely removed based on postoperative pathology, and follow-up is conducted.
Interested in participating?
Request Info18 year–70 year
Female
Interventional
Not applicable
Xi'an, Shaanxi, 710032, China
Location status: Recruiting
This is a single-arm and single-center clinical study. The specific implementation steps of the study are as follows:
Evaluate the patients and select those with better compliance and a standardized total score of the scale ≥80. Introduce in detail the research purpose, methods, risks and benefits, etc. to the patients who meet the inclusion criteria and the assessment, and obtain the written informed consent forms of the patients.
Complication assessment: Observe whether complications such as bleeding, infection, breast tissue injury, poor incision healing, and lymphatic leakage occur in patients during vacuum-assisted resection and subsequent surgeries. Record the occurrence time, severity, and treatment measures of complications. Evaluation of surgical satisfaction, treatment satisfaction and quality of life satisfaction: After the operation, give chemotherapy, targeted therapy or endocrine therapy according to the diagnosis and treatment routine. The treatment plan follows the recommendations of guidelines such as NCCN. If local radiotherapy is required, carry it out according to the clinical routine. At 1 week, 1 month, 3 months and 6 months after the operation at time points such as months, evaluate the surgical satisfaction, treatment satisfaction and quality of life satisfaction of the patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
:
Subjects must meet all of the following inclusion criteria to be enrolled in this trial:
Exclusion criteria
:
Those with any of the following circumstances will not be selected as subjects:
Patients undergoing VAE surgery (EnCor® vacuum-assisted minimally invasive rotary system)are placed in an appropriate position, undergo routine disinfection and blanching, and the tumor location is located by ultrasound. After local anesthesia, a vacuum-assisted rotary cutting needle is percutaneous punctured beneath the tumor. Under ultrasound guidance, the tumor tissue is gradually resected until the ultrasound shows complete tumor resection. The resected tissue is sent for pathological examination. After the patient is confirmed to have breast cancer through VAE resection biopsy, depending on the patient's specific condition, they are hospitalized for radical mastectomy. The surgical methods can be breast-conserving surgery or mastectomy. At the same time, sentinel lymph node biopsy is performed, and the resected tissue is sent for pathological examination. The surgical process follows the surgical treatment norms for breast cancer.
Time frame: Two weeks after the operation
The proportion of patients whose tumor tissues are completely resected by VAE confirmed through postoperative pathological examination, that is, the false negative rate of VAE
Time frame: During the operation, 3 days after the operation, 2 weeks after the operation, 1 month after the operation
The occurrence of complications such as bleeding, infection, breast tissue injury, poor incision healing and lymphatic leakage during VAE and subsequent surgical procedures
Time frame: Two years after the operation
The patients are followed up to evaluate whether there is recurrence of breast and axillary lesions
Time frame: Three months after the operation
The BREAST Q2 questionnaire is used for the investigation
Contact information is provided by the study sponsor or research team.
Xijing Hospital
Other
A Single-center, Single-arm, Open Study on the Treatment of Early Small Breast Cancer With Ultrasound-guided Vacuum-assisted Excision Combined With Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07661927
Breast Cancer (Early Breast Cancer), Breast Diseases
Angers, France
View Trial DetailsNCT07447414
Breast Cancer, Breast Cancer (Early Breast Cancer)
Lugo, Spain
View Trial DetailsNCT07379918
Breast Cancer (Early Breast Cancer), Breast Cancer Prognostic
Paris, France
View Trial DetailsNCT02338167
Advanced/Metastatic Breast Cancer, Breast Cancer (Early Breast Cancer)
Böblingen, Baden-Wurttemberg, Germany
View Trial Details